全文获取类型
收费全文 | 985561篇 |
免费 | 102325篇 |
国内免费 | 2949篇 |
专业分类
耳鼻咽喉 | 15531篇 |
儿科学 | 27932篇 |
妇产科学 | 27827篇 |
基础医学 | 130990篇 |
口腔科学 | 30856篇 |
临床医学 | 103751篇 |
内科学 | 192838篇 |
皮肤病学 | 20614篇 |
神经病学 | 84693篇 |
特种医学 | 40006篇 |
外国民族医学 | 173篇 |
外科学 | 158685篇 |
综合类 | 25400篇 |
现状与发展 | 42篇 |
一般理论 | 296篇 |
预防医学 | 82134篇 |
眼科学 | 23385篇 |
药学 | 68615篇 |
1篇 | |
中国医学 | 1661篇 |
肿瘤学 | 55405篇 |
出版年
2020年 | 8646篇 |
2018年 | 14859篇 |
2017年 | 13455篇 |
2016年 | 14680篇 |
2015年 | 16184篇 |
2014年 | 22239篇 |
2013年 | 29861篇 |
2012年 | 28965篇 |
2011年 | 30131篇 |
2010年 | 21757篇 |
2009年 | 22890篇 |
2008年 | 28259篇 |
2007年 | 29572篇 |
2006年 | 30379篇 |
2005年 | 28591篇 |
2004年 | 27207篇 |
2003年 | 26170篇 |
2002年 | 24898篇 |
2001年 | 37821篇 |
2000年 | 37751篇 |
1999年 | 32812篇 |
1998年 | 11519篇 |
1997年 | 10561篇 |
1996年 | 10525篇 |
1995年 | 9770篇 |
1994年 | 8941篇 |
1992年 | 27458篇 |
1991年 | 26801篇 |
1990年 | 26191篇 |
1989年 | 25254篇 |
1988年 | 23776篇 |
1987年 | 23323篇 |
1986年 | 22151篇 |
1985年 | 21478篇 |
1984年 | 16712篇 |
1983年 | 14344篇 |
1982年 | 9172篇 |
1981年 | 8470篇 |
1979年 | 16830篇 |
1978年 | 12272篇 |
1977年 | 10305篇 |
1976年 | 9428篇 |
1975年 | 10232篇 |
1974年 | 12723篇 |
1973年 | 12210篇 |
1972年 | 11619篇 |
1971年 | 10732篇 |
1970年 | 10289篇 |
1969年 | 9937篇 |
1968年 | 8912篇 |
排序方式: 共有10000条查询结果,搜索用时 250 毫秒
81.
82.
83.
84.
85.
Bhavana Pothuri Allison L. Brodsky Joseph A. Sparano Stephanie V. Blank Mimi Kim Dawn L. Hershman Amy Tiersten Brian F. Kiesel Jan H. Beumer Leonard Liebes Franco Muggia 《Cancer chemotherapy and pharmacology》2020,85(4):741-751
Poly(ADP-ribosyl) polymerases (PARPs) are nuclear enzymes with roles in DNA damage recognition and repair. PARP1 inhibition enhances the effects of DNA-damaging agents like doxorubicin. We sought to determine the recommended phase two dose (RP2D) of veliparib with pegylated liposomal doxorubicin (PLD) in breast and recurrent gynecologic cancer patients. Veliparib and PLD were administered in a standard phase 1, 3 + 3 dose-escalation design starting at 50 mg veliparib BID on days 1–14 with PLD 40 mg/mg2 on day 1 of a 28-day cycle. Dose escalation proceeded in two strata: A (prior PLD exposure) and B (no prior PLD exposure). Patients underwent limited pharmacokinetic (PK) sampling; an expansion PK cohort was added. 44 patients with recurrent ovarian or triple negative breast cancer were enrolled. Median age 56 years; 23 patients BRCA mutation carriers; median prior regimens four. Patients received a median of four cycles of veliparib/PLD. Grade 3/4 toxicities were observed in 10% of patients. Antitumor activity was observed in both sporadic and BRCA-deficient cancers. Two BRCA mutation carriers had complete responses. Two BRCA patients developed oral squamous cell cancers after completing this regimen. PLD exposure was observed to be higher when veliparib doses were > 200 mg BID. The RP2D is 200 mg veliparib BID on days 1–14 with 40 mg/m2 PLD on day 1 of a 28-day cycle. Anti-tumor activity was seen in both strata. However, given development of long-term squamous cell cancers and the PK interaction observed, efforts should focus on other targeted combinations to improve efficacy. 相似文献
86.
Nurse perceptions of the Nursing Delirium Screening Scale in two palliative care inpatient units: a focus group study 下载免费PDF全文
87.
L.‐Q. Zheng X.‐C. Han Y. Huang H.‐W. Li X.‐D. Niu J. Li 《Clinical and experimental dermatology》2015,40(3):293-297
Porocarcinoma is an unusual, locally aggressive and potentially fatal neoplasm. Several cutaneous malignancies have been described in association with porocarcinoma, including squamous cell carcinoma, basal cell carcinoma and tricholemmal carcinoma. Previous reports have indicated that the occurrence of malignant tumours in combination with porocarcinoma is extremely rare, in particular with regard to Bowen disease (BD). We report an uncommon case of porocarcinoma occurring synchronously in a single BD lesion in a 63‐year‐old woman with multiple BD lesions. The clinical and histological findings confirmed this diagnosis. 相似文献
88.
Benyam Kinde Harrison W. Gabel Caitlin S. Gilbert Eric C. Griffith Michael E. Greenberg 《Proceedings of the National Academy of Sciences of the United States of America》2015,112(22):6800-6806
DNA methylation at CpG dinucleotides is an important epigenetic regulator common to virtually all mammalian cell types, but recent evidence indicates that during early postnatal development neuronal genomes also accumulate uniquely high levels of two alternative forms of methylation, non-CpG methylation and hydroxymethylation. Here we discuss the distinct landscape of DNA methylation in neurons, how it is established, and how it might affect the binding and function of protein readers of DNA methylation. We review studies of one critical reader of DNA methylation in the brain, the Rett syndrome protein methyl CpG-binding protein 2 (MeCP2), and discuss how differential binding affinity of MeCP2 for non-CpG and hydroxymethylation may affect the function of this methyl-binding protein in the nervous system. 相似文献
89.
Dynamic LVOT Obstruction and Aortic Stenosis in the Same Patient: A Case of Challenging Doppler Hemodynamics 下载免费PDF全文
Matthew W. Parker M.D. Francis J. Kiernan M.D. 《Echocardiography (Mount Kisco, N.Y.)》2015,32(6):1030-1032
We present a patient with both dynamic left ventricular outflow tract obstruction and valvular aortic stenosis. The aortic valve was calcified, and velocities and gradients measured by continuous‐wave Doppler met standard criteria for severe aortic stenosis. The increased subvalvular velocities invalidated assumptions of the simplified Bernoulli equation; correction using the longer form of the Bernoulli equation suggested a lower but still significant gradient. The complex shape of the subvalvular spectral Doppler envelope indicated supranormal systolic function and dynamic left ventricular outflow obstruction. Left heart catheterization with an end‐hole catheter was required to determine the subvalvular and valvular components of the obstruction. 相似文献
90.